Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02938949 · ClinicalTrials.gov registry record · Phase 4
Alirocumab in Patients With Acute Myocardial Infarction
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT02938949 is a Phase 4 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 20 participants.
The verdict
NCT02938949, a Phase 4 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to high-intensity statin (atorvastatin 80 mg) in lowering low density lipoprotein (LDL) cholesterol during non-ST segment elevation myocardial infarction (NSTEMI).
Interventions
- DRUG placebo
- DRUG alirocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-01 |
| Est. Completion | 2018-08-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02938949
The ClinicalTrials.gov registry entry for NCT02938949 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02938949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02938949 about?
NCT02938949 is a clinical study titled "Alirocumab in Patients With Acute Myocardial Infarction". Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to high-intensity statin (atorvastatin 80 mg) in lowering low density lipoprotein (LDL) cholesterol during non-ST segment elev...
What is the current status of trial NCT02938949?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2017-01. Estimated completion is 2018-08-16.
What interventions are being tested in trial NCT02938949?
The interventions under investigation include: placebo (DRUG), alirocumab (DRUG).
Who is sponsoring clinical trial NCT02938949?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.